Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.69 |
| ▸ | LTA4H | P09960 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20224804 | 0.91 | DRD2 (0.67) | DRD2LTA4HMEN1ALDH1A1LMNA | |
| SCHEMBL17848556 | 0.89 | DRD2 (0.85) | DRD2LTA4HPLA2G7 | |
| SCHEMBL17848335 | 0.84 | DRD2 (0.71) | DRD2LTA4HMEN1ALDH1A1LMNA | |
| SCHEMBL25464878 | 0.83 | DRD2 (0.80) | DRD2 | |
| SCHEMBL20224807 | 0.82 | DRD2 (0.85) | DRD2LTA4HTMEM97SIGMAR1 | |
| SCHEMBL17848482 | 0.82 | DRD2 (0.71) | DRD2LTA4H | |
| SCHEMBL17848614 | 0.82 | DRD2 (1.00) | DRD2LTA4HALDH1A1 | |
| SCHEMBL17848595 | 0.82 | DRD2 (0.78) | DRD2LTA4HPLA2G7TMEM97SIGMAR1 | |
| SCHEMBL17848374 | 0.82 | DRD2 (0.78) | DRD2LTA4H | |
| SCHEMBL17848461 | 0.82 | DRD2 (1.00) | DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | DRD2 1/4885LTA4H 2669/4885MEN1 4669/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | DRD2 1/4885LTA4H 2479/4885MEN1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.